TWD
ALNY icon

True Wealth Design’s Alnylam Pharmaceuticals ALNY Stock Holding History

True Wealth Design’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.6K Buy
95
+19
+25% +$5.73K 0.01% 692
2026
Q1 		$25.1K Sell
76
-79
-51% -$26.9K 0.01% 624
2025
Q4 		$61.5K Sell
155
-73
-32% -$32.3K 0.02% 281
2025
Q3 		$104K Buy
228
+214
+1,529% +$87.1K 0.03% 158
2025
Q2 		$4.6K Sell
14
-285
-95% -$78.9K ﹤0.01% 838
2025
Q1 		$80.8K Buy
299
+147
+97% +$37.8K 0.03% 120
2024
Q4 		$35.8K Sell
152
-2
-1% -$526 0.01% 231
2024
Q3 		$42.4K Buy
154
+153
+15,300% +$39.8K 0.02% 166
2024
Q2 		$243 Sell
1
-1
-50% -$158 ﹤0.01% 734
2024
Q1 		$299 Buy
2
+1
+100% +$167 ﹤0.01% 713
2023
Q4 		$192 Hold
1
– – ﹤0.01% 682
2023
Q3 		$178 Hold
1
– – ﹤0.01% 662
2023
Q2 		$190 Hold
1
– – ﹤0.01% 657
2023
Q1 		$201 Hold
1
– – ﹤0.01% 730
2022
Q4 		$238 Buy
+1
New +$213 ﹤0.01% 637

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

True Wealth Design's ALNY Position: Q2 2026 in Review

True Wealth Design increased its Alnylam Pharmaceuticals (ALNY) stake by 25% in Q2 2026, buying an estimated $5.73K and bringing the position to 95 shares worth $28.6K. The position accounts for 0.01% of the portfolio, ranked #692.

True Wealth Design first reported a position in ALNY in Q4 2022 and has held it in 15 quarters since. The position peaked at $104K in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • True Wealth Design held 95 shares of Alnylam Pharmaceuticals worth $28.6K as of Q2 2026.
  • True Wealth Design bought 19 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $5.73K.
  • Alnylam Pharmaceuticals made up 0.01% of True Wealth Design's portfolio in Q2 2026, its #692 holding.
  • True Wealth Design first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • True Wealth Design's Alnylam Pharmaceuticals position peaked at $104K in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.